A Study With Imlifidase in Anti-GBM Disease
Public ClinicalTrials.gov record NCT05679401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
Study identification
- NCT ID
- NCT05679401
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Imlifidase Drug
- Plasma exchange (PLEX) Procedure
- Cyclophosphamide (CYC) Drug
- Glucocorticoids Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2022
- Primary completion
- Jun 22, 2025
- Completion
- Feb 1, 2026
- Last update posted
- Mar 3, 2026
2022 – 2026
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center Plaza | Los Angeles | California | 90024 | — |
| John Hopkins Medical Institution | Baltimore | Maryland | 21287 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Minnesota Health Clinical Research Unit | Minneapolis | Minnesota | 55455 | — |
| UNC Kidney Center/Division of Nephrology & Hypertension | Chapel Hill | North Carolina | 27599-7155 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05679401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05679401 live on ClinicalTrials.gov.